垂体瘤转化基因

摘要： 目的:探讨垂体瘤转化基因(PTTG)、血管内皮生长因子-C(VEGF-C)表达水平与ⅠB-ⅡA期宫颈鳞癌患者淋巴转移及宫旁浸润的关系.方法:收集40例ⅠB-ⅡA期宫颈浸润性鳞癌(SCC)组织标本(SCC组)与20例宫颈慢性炎组织标本(炎症组),采用免疫组织化学方法测定宫颈组织标本中PTTG及VEGF-C表达,并分析PTTG、VEGF-C表达与SCC临床病例特征(年龄、FIGO分期、肿瘤直径、浸润深度、淋巴转移、淋巴脉管间隙浸润、宫旁切缘及宫旁是否受侵)的关系,采用Spearman等级相关分析PTTG、VEGF-C表达的相关性.结果:SSC组PTTG和VEGF-C表达阳性率显著高于炎症组(P＜0.05),PTTG表达水平与肿瘤分化程度、浸润深度、淋巴脉管间隙浸润以及淋巴结转移有关(P＜0.05),VEGF-C表达水平与浸润深度和淋巴结转移有关(P＜0.05);在SSC组织中,PTTG与VEGF-C表达水平呈正相关(r=0.69,P＜0.05).结论:PTTG和VEGF-C在SCC组织中表达上调,可能参与了肿瘤浸润与淋巴转移过程.%Objective:To explore the relationship between the expression level of pituitary tumortransforming gene (PTTG),vascular endothelial growth factor-C (VEGF-C) and the lymph node metastasis and parametrial infiltration in patients with squamous carcinoma of cervix(SCC) in Stage Ⅰ B-Ⅱ A.Methods:40 cases of tissue specimens with invasive SCC in Stage Ⅰ B-Ⅱ A and 20 cases of tissue specimens with cervical chronic inflammation were collected as the SCC group and the inflammation group respectively.The expression levels of PTTG and VEGF-C were compared by immunohistochemistry,and the relationship between the expression level of PTTG and VEGF-C and the SCC pathological feature,and the relationship between the expression level of PTTG and VEGF-C were analyzed.Restlts:The positive rates of PTTG and VEGF-C expression in the SCC group were significantly higher than those in the inflammation group (P ＜ 0.05).The expression level of PTTG was correlated with tumor differentiation degree,the depth of invasion,lymph-vascular space infiltration and lymph node metastasis (P ＞ 0.05),but the expression level of VEGF-C was related to the depth of invasion and lymph node metastasis (P ＜ 0.05).In SCC tissues,there was a positive correlation between the PTTG and VEGF-C expression (r =0.69,P ＜ 0.05).Conclusions:PTTG and VEGF-C are up-regulated in SCC tissues and are involved in tumor infiltration and lymph node metastasis,and both can be new targets for the diagnosis and treatment of SCC.

摘要： 目的 探讨肿瘤标志物、垂体瘤转化基因(PTTG)、血管内皮生长因子受体3(VEGFR-3)及血流动力学指标在宫颈良恶性病变患者中的表达及临床意义.方法 选取2012年3月-2016年2月该院收治且经病理确诊的98例宫颈病变患者的临床资料.所有患者术中均留取宫颈组织标本,入院后均采集血样,采用免疫组织化学法测定PPTG、VEGFR-3表达情况,并测定血清鳞状细胞癌抗原(SCC)、糖类抗原19-9(CA199)、糖类抗原125(CA125)水平,检测微血管密度(MVD).采用多普勒超声测定收缩期峰值血流速度(PSV)、舒张末血流速度(EDV)及血管阻力指数(RI),分析宫颈良恶性病变患者上述指标的表达情况及临床意义.结果 ①慢性宫颈炎患者SCC、CA199及CA125水平均低于宫颈上皮内瘤样病变(CIN)患者与宫颈浸润癌患者(P<0.05),CIN患者上述水平低于宫颈浸润癌患者(P<0.05);②CIN、宫颈浸润癌PTTG、VEGFR-3表达阳性率高于慢性宫颈炎(P<0.05),宫颈浸润癌PTTG、VEGFR-3表达阳性率高于CIN(P<0.05);③慢性宫颈炎MVD低于CIN、宫颈浸润癌(P<0.05),CIN MVD低于宫颈浸润癌(P<0.05);④CIN、宫颈浸润癌PSV、EDV均高于慢性宫颈炎(P<0.05),RI低于慢性宫颈炎(P<0.05),宫颈浸润癌PSV、EDV高于CIN,RI低于CIN(P<0.05).结论 宫颈浸润癌患者血清肿瘤标志物表达水平高,癌组织PTTG、VEGFR阳性率高、MVD高,血流速度快、血管阻力低,与宫颈良性病变患者有差异.

摘要： 目的：探讨垂体瘤转化基因（PTTG）、血管内皮生长因子-C（VEGF-C）表达水平与ⅠB-ⅡA期宫颈鳞癌患者淋巴转移及宫旁浸润的关系。方法：收集40例ⅠB-ⅡA期宫颈浸润性鳞癌（SCC）组织标本（SCC组）与20例宫颈慢性炎组织标本（炎症组）,采用免疫组织化学方法测定宫颈组织标本中PTTG及VEGF-C表达,并分析PTTG、VEGF-C表达与SCC临床病例特征（年龄、FIGO分期、肿瘤直径、浸润深度、淋巴转移、淋巴脉管间隙浸润、宫旁切缘及宫旁是否受侵）的关系,采用Spearman等级相关分析PTTG、VEGFC表达的相关性。结果：SSC组PTTG和VEGF-C表达阳性率显著高于炎症组（P〈0.05）,PTTG表达水平与肿瘤分化程度、浸润深度、淋巴脉管间隙浸润以及淋巴结转移有关（P〈0.05）,VEGF-C表达水平与浸润深度和淋巴结转移有关（P〈0.05）;在SSC组织中,PTTG与VEGFC表达水平呈正相关（r=0.69,P〈0.05）。结论：PTTG和VEGFC在SCC组织中表达上调,可能参与了肿瘤浸润与淋巴转移过程。

摘要： Objective To explore the effects of PTTG gene expression on the reproductive ability of non-hodgkin lymphoma cells SUDHL-4 .Methods Non-Hodgkin Lymphoma cells SUDHL-4 was chose to show the biology behavior changes after si-lence PTTG by shRNA ,through the MTT test ,and cell cycle analysis .Results After silence PTTG by shRNA ,the prolifera-tion of SUDHL-4 cells were significantly decreased ,the ratio of G0/G1 and S phase cells was decreased ,the ratio of G2/M cells was increased ,and cell cycle arrested at G2/M ,the difference was statistically significant (P<0.05) .Conclusion The overex-pression of PT TG gene may be related to the occurrence and development of lymphoma ,and it may become the molecular diag-nostics and new therapy target of lymphoma .%目的：观察垂体瘤转化基因（pituitary tumor-transforming gene ，PTTG）对非霍奇金淋巴瘤细胞SUDHL-4增殖能力的影响。方法通过shRNA的方法在高表达PTTG的SUDHL-4细胞中敲降PTTG基因，通过MTT实验、细胞周期分析检测SUDHL-4生物学行为的变化。结果 PTTG被敲降后SUDHL-4细胞的生长速度明显下降，细胞G0／G1比例、S期比例下降；G2／M期比例升高，细胞阻滞于G2／M期，差异均有统计学意义（P＜0.05）。结论 PTTG基因可能在非霍奇金淋巴瘤的发生发展中起重要作用，可能成为判断非霍奇金淋巴瘤预后的分子标志物及临床治疗的靶点。

摘要： 目的：探讨微小 RNA （ miRNA ）对垂体瘤细胞株中增生细胞核抗原（ ki－67）、垂体瘤转化基因（ PTTG ）、血管内皮细胞生长因子（ VEGF）表达影响。方法将培养好的人垂体瘤细胞放入A、B两培养瓶中培养，其中A培养瓶培养基中加入标记的 miRNA基因2μl，而 B 培养瓶只是加入等量的培养基，采用RT－PCR及 Western印迹法检测培养24 h后人垂体瘤细胞中ki－67、PTTG、VEGF基因及蛋白表达水平。结果①A培养瓶加标记的miRNA基因后培养24 h，人垂体瘤细胞ki－67、PTTG和VEGF mRNA表达水平明显低于B培养瓶（P＜0．05）；②A培养瓶加入miRNA基因后培养24 h，人垂体瘤细胞ki－67、PTTG和VEGF蛋白表达水平明显低于B培养瓶（P＜0．05）。结论垂体瘤细胞中 ki－67、PTTG、VEGF处于高水平表达，而miRNA能够明显降低ki－67、PTTG、VEGF的表达，抑制细胞的生长，对临床具有指导意义。

摘要： Objective To investigate the pituitary tumor transforming gene (PTTG) expression pattern in pituitary cell senescence and pituitary adenoma tumorigenesis. Methods D-galactose induced F344 rats aging model. The rats aging expression and tumor generation condition were observed through pathological detection, molecular biology method was used to measure the expression of PTTG, P53, P21, P16 in pituitary tissue. Results ①D-galactose induced F344 rats showed significant characteristics of aging and oestrogen induced rats successfully generated prolactin adenoma; ②ag-ing Rats visible cytoplasmic vacuoles occurred, heterochromatin exists in the pituitary cell, pituitary PRL immunohisto-chemical was strong positive in tumor group rats; ③RT-PCR showed that PTTG mRNA expression in estrogen induced pituitary adenoma group was (12.99±1.86), PTTG expression of D-galactose induced aging group was (2.10±0.23), the difference was statistically significant (P<0.01); P53, P16, P21 mRNA expression of D-galactose induced aging group was (113.51±23.87), (29.26±4.44), (67.21±10.08), P53, P16, P21 mRNA expressed in estrogen induction of pituitary adenoma group was (83.26±8.06), (9.83±2.13), (28.19±2.01), the differences were statistically significant (P< 0.05); ④Western-blot strip integral grey value showed PTTG, P21 and P16 protein expression of D-galactose induced aging group was (0.198±0.032), (1.239±0.051), (1.673±0.055) and expressed in estrogen induced pituitary adenoma group was (1.002±0.041), (0.202±0.055), (0.409±0.059), the differences were statistically significant (P<0.05). Conclusion PTTG over-expression leads to senescence bypassed pituitary adenoma formation, PTTG weak expression leads to senescence. P16, P21 are important regulatory factors in pituitary cell senescence.%目的：探讨垂体瘤转化基因(PTTG)在垂体细胞衰老和垂体瘤中表达规律。方法构建F344大鼠D-半乳糖诱导衰老模型和雌激素诱导泌乳素腺瘤模型。观察大鼠的衰老表型及成瘤情况，对大鼠垂体进行病理学检测，分子生物学方法检测垂体PTTG、P53、P21、P16蛋白表达。结果①D-半乳糖成功诱导大鼠出现明显衰老特征，雌激素诱导大鼠成功生成泌乳素腺瘤；②衰老大鼠垂体胞质内有空泡和异染色质生成，肿瘤大鼠垂体PRL免疫组化为强阳性；③RT-PCR显示雌激素诱导组PTTG mRNA表达为(12.99±1.86)，D-半乳糖诱导衰老组PTTG表达为(2.10±0.23)，差异有高度统计学意义(P<0.01)；D-半乳糖诱导衰老组P53、P16、P21 mRNA表达为(113.51±23.87)、(29.26±4.44)、(67.21±10.08)，在雌激素诱导垂体瘤组中表达为(83.26±8.06)、(9.83±2.13)、(28.19±2.01)，两组比较差异有统计学意义(P<0.05)。④Western-blot条带积分灰度值显示D-半乳糖诱导衰老组PTTG、P21、P16蛋白表达为(0.198±0.032)、(1.239±0.051)、(1.673±0.055)，雌激素诱导垂体瘤中表达为(1.002±0.041)、(0.202±0.055)、(0.409±0.059)，两组比较差异有统计学意义(P<0.05)。结论 PTTG基因过表达导致衰老绕过，垂体瘤形成。 PTTG表达减弱，诱导衰老。 P16、P21是垂体细胞衰老重要的调控因子。

摘要： Objective To observe the effect of small interfering RNA (siRNA) silencing pituitary tumor transforming gene (PTTG) on the growth of primary cultured human prolactin pituitary adenoma cells (HPAs).Methods After the HPAs were primary cultured and steadily subcultured,the cells were divided into three groups:the blank control group,the negative control group and the siRNA-PTTG transfection group.After 48 h of infection,proliferation rate of HPAs was measured by using cell counting kit-8 (CCK-8).Transfection efficiency and the apoptosis rate were tested by using flow cytometry.The expression of PTTG mRNA and protein were detected by using reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting respectively.Caspase-3 activity was measured by Caspase activity assay kit.Prolactin changes in cell supernatants were measured by radioimmunoassay.Results Compared to the blank cotnrol group and the negative control group,the transcription of PTTG mRNA and the expression of PTTG protein were significantly down-regulated in the siRNA-PTTG transfection group,and the proliferation was suppressed [the inhibition rate in the negative control group and the siRNA-PTTG transfection group was (3.02 ± 1.77) ％ and (25.38 ± 0.11) ％ respectively (P ＜ 0.05),while the apoptosis was significantly increased [the apoptosis rate in the blank control group,negative control group and siRNA-PTTG transfection group was (6.21 ± 2.36) ％,(7.23 ± 3.56) ％ and (32.33 ± 5.69) ％ respectively (P ＜ 0.05).The activity of Caspase-3 was increased (P ＜ 0.05),and the radioimmunoassay revealed that the prolactin level in the cell supernatants was significantly decreased in the siRNA-PTTG transfection group,32.9％ of the blank control group (P ＜ 0.05).Conclusion Down-regulation of PTTG expression can suppress the proliferation and induce apoptosis of HPAs,which results in the reduction of prolactin secretion.%目的 观察小干扰RNA(siRNA)沉默垂体瘤转化基因(PTTG)对原代培养的人泌乳素型垂体瘤细胞(HPAs)生长的影响.方法 原代培养人泌乳素型垂体腺瘤细胞,稳定传代后分为3组:空白对照组、阴性对照组、siRNA-PTTG转染组,转染48 h后细胞计数试剂盒(CCK-8)法检测各组细胞增殖能力;流式细胞仪检测细胞凋亡率;逆转录聚合酶链反应(RT-PCR)和Western blot法测定PTTG mRNA、蛋白的表达;半胱氨酸天冬氨酸蛋白酶(Caspase)试剂盒检测Caspase-3的活性;放射免疫法测定各组细胞上清中泌乳素的水平.结果 与空白对照组及阴性对照组比较,siRNA-PlTG转染组HPAs细胞PTTG mRNA和蛋白表达明显下调,细胞增殖受到抑制[阴性对照组、转染组抑制率分别为(3.02±1.77)％、(25.38±0.11)％,P＜0.05],凋亡明显增多[3组凋亡率分别为:(6.21±2.36)％、(7.23±3.56)％、(32.33±5.69)％,P＜0.05],Caspase-3活性增加(P＜0.05);放射免疫法显示siRNA-PTTG转染组上清中泌乳素分泌水平下降,为空白对照组的32.9％ (P ＜0.05).结论 下调PTTG基因可抑制人泌乳素型垂体瘤细胞生长,促进其凋亡,从而降低泌乳素分泌水平.

摘要： Objective To explore the expression of pituitary tumor transforming gene (PTTG) and c-myc gene in patients with non-Hodgkin lymphoma (NHL),its relationship with NHL and its clinical significance.Methods PTTG mRNA and c-myc mRNA levels in bone marrow mononuclear cell (BMMNC) isolated from 38 NHL patients and 10 chronic lymphadenitis patients were quantified by reverse transcriptionpolymerase chain reaction (RT-PCR).Results mRNA expression of PTTG and c-myc gene in BMMNC was significantly higher in NHL patients than those in normal controls (PTTG:0.567 7±0.270 7 vs 0.071 2± 0.020 1,t =4.706,P ＜ 0.05; c-myc:0.352 6±0.185 4 vs 0.107 3±0.043 5,t =3.303,P =0.002).The expression of PTTG and c-myc gene in peripheral T cell lymphoma and diffuse large B cell lymphoma showed no significant difference (PTTG:0.556 8±0.211 3 vs 0.602 8±0.244 6,t =0.640,P =0.527; c-myc:0.350 1± 0.177 6 vs 0.361 0±0.190 2,t =0.302,P =0.765).Both expression of PTTG and c-myc were positively related to NHL clinical stage and IPI.Expression of PTTG mRNA was positively related to the expression of c-myc mRNA.Conclusion There was overexpression of PTTG and c-myc in NHL,which indicates that PTTG might be involved in tumorigenesis of NHL through direct or indirect activation of c-myc oncogene.%目的 探讨非霍奇金淋巴瘤(NHL)患者骨髓垂体瘤转化基因(PTTG)与c-myc基因的表达及其临床意义.方法 采用反转录聚合酶链反应(RT-PCR)法检测38例NHL患者骨髓及10例慢性淋巴结炎患者骨髓单个核细胞(BMMNC)中PTTG及c-myc基因的表达.结果 NHL患者骨髓中PTTG和c-myc基因的表达水平均明显高于慢性淋巴结炎组,差异有统计学意义(PTTG:0.567 7±0.270 7比0.071 2±0.020 1,t=4.706,P＜0.05; c-myc:0.352 6±0.185 4比0.107 3±0.043 5,t=3.303,P=0.002).外周T细胞淋巴瘤和弥漫大B细胞淋巴瘤患者PTTG及c-myc基因表达水平差异均无统计学意义(PTTG:0.556 8±0.211 3比0.602 8±0.244 6,t=0.640,P=0.527;c-myc:0.350 1±0.177 6比0.361 0±0.190 2,t=0.302,P=0.765).PTTG基因的表达与NHL骨髓浸润、国际预后指数(IPI)评分呈正相关(r=0.422,r=0.387;均P＜0.05).c-myc基因的表达与NHL骨髓浸润、IPI评分呈正相关(r=0.431,r=0.344,均P＜0.05).NHL患者骨髓PTTG基因和c-myc基因的表达呈正相关(r=0.490,P＜0.05).结论 NHL中PTTG、c-myc呈高表达状态,PTTG可能通过直接或间接途径促进c-myc的高表达.

摘要： 无功能垂体腺瘤(non-functioning pituitary adenomas,NFPA)手术治疗后部分病人复发。复发 NFPA 的处理一直是临床上比较棘手的问题。如何能够早期预测肿瘤复发并采取适当的处理措施,目前尚有争论。近年来,在预测 NFPA 复发及治疗方面取得一些新的进展,本文就此作一综述。

摘要： Objective To explore the expression of PTTG in patients with non-Hodgkin's lymphoma ( NHL), its relationship with NHL and its clinical significance.Method PTTG gene expression on bone marrow mononuclear cell (BMMNC) in 32 patients with non-hodgkin Lymphoma (NHL) and 10 patients with chronic lymphadenitis were detected by RT-PCR method. Results 18 of 32 (56.3%) cases with NHL were observed with PTTG gene expression, among which there were peripheral T cell lymphoma 55.6%(5/9 cases), 56.5% (13/23 cases) of diffuse large B cell lymphoma.PTTG gene expression levels of patients with NHL were significantly higher than those in patients with chronic lymphadenitis ( P0.05 ) .Conclu-sion The overexpression of PTTG gene may be related to the occurrence and development of lymphoma .%目的：研究垂体瘤转化基因（ pituitary tumor-transforming gene， PTTG）在淋巴瘤患者中的表达，探讨其与淋巴瘤发生的关系及临床意义。方法采用RT-PCR方法检测32例非霍奇金淋巴瘤（ non-Hodgkin's Lymphoma， NHL）及10例慢性淋巴结炎患者骨髓单个核细胞（bone marrow mononuclear cell， BMMNC）中PTTG 基因的表达。结果32例NHL患者有18例（56.3％）存在PTTG基因的表达，其中外周T细胞淋巴瘤有55.6％（5/9例）、弥漫大B细胞淋巴瘤有56.5％（13/23例）。 NHL患者PTTG基因的表达水平明显高于慢性淋巴结炎患者（P＜0.05），外周T细胞淋巴瘤和弥漫大B细胞淋巴瘤患者PTTG基因的表达水平差异无统计学意义（ P＞0.05）。结论 PTTG基因的过度表达可能和淋巴瘤的发生发展有关。

摘要： 目的：研究溴隐亭对大鼠垂体腺瘤细胞(MMQ细胞)泌乳素(PRL)分泌及PTTG(垂体瘤转化基因)和VEGF(血管内皮生长因子)表达的影响,初步探讨溴隐亭缩小肿瘤的作用机制是否依赖于改变PTTG和VEGF因子的表达.rn 方法：改良MTT法计算溴隐亭的半数抑制浓度IC50;用ELISA方法检测细胞胞上清液PRL浓度;RT-PCR检测MMQ细胞中PTTG和VEGF mRNA的表达.rn 结果：溴隐亭对MMQ细胞48小时的IC50值为0.42μg/ml;随着溴隐亭浓度的递增和干预时间延长,MMQ细胞外液中PRL浓度呈逐渐下降趋势;RT-PCR检测可见到加入不同浓度溴隐亭干预48h后,MMQ细胞中PTTG和VEGF的mRNA表达程度下降,3组不同浓度组之间比较,P＜0.05,差异有统计学意义.rn 结论：溴隐亭可以有效的降低MMQ细胞分泌的PRL水平,在分子水平上,影响MMQ细胞中PTTG和VEGF的mRNA的表达,PTTG及VEGF表达水平的下降,可能与溴隐亭治疗后,肿瘤的缩小存在相关性,其作用机制有待进一步研究.

摘要： 本发明公开了NFIC基因可以作为垂体瘤早期诊断的分子标志物。本发明的实验证明，与正常垂体组织相比，垂体瘤组织中NFIC基因表达显著升高，且经过RNA干扰实验证明NFIC能够影响垂体瘤细胞的增殖。根据本发明的研究成果，可以研发能够抑制NFIC基因表达的药物，从而实现临床上对于垂体瘤的预防和治疗。

摘要： 本发明公开了SMR3B基因在垂体瘤诊治中的应用，SMR3B基因在垂体瘤患者组织中呈差异性表达，增加SMR3B的表达可以促进垂体瘤细胞的凋亡，本发明公开了垂体瘤诊断和治疗的方法，大大提高了垂体瘤诊断的敏感性和特异性，同时为垂体瘤的基因治疗提供了新的靶点。

摘要： 本发明公开了MUC21基因及其表达产物在垂体瘤诊疗中的用途，本发明通过生物信息学方法筛选到与垂体瘤发生发展相关的基因MUC21，并采用荧光定量等方法进行功能验证，MUC21基因在垂体瘤患者组织中表达下调，增加MUC21基因的表达可以抑制垂体瘤细胞的过度增殖。本发明还公布了诊断垂体瘤的产品和治疗垂体瘤的药物组合物。

摘要： 本发明涉及一种垂体瘤致病基因CCNB1及其应用。本发明运用生物信息学方法筛选到一个垂体瘤致病相关基因CCNB1，并运用荧光定量PCR方法对筛选到的垂体瘤致病基因CCNB1进行功能分析，结果显示筛选得到的CCNB1与垂体瘤具有很好的相关性，可用于制备垂体瘤辅助诊断或者预后制剂。本发明还公布了一种检测CCNB1表达水平的荧光定量PCR试剂盒及其使用方法，该试剂盒灵敏度高，定量快速准确、稳定性好，具有良好的应用前景。

摘要： 本发明公开了一种方便分离垂体瘤的垂体瘤取样装置，包括底板、支撑脚、万向轮、支撑杆一、伸缩杆一、固定板一、托架、支撑杆二、绕线杆、底盘、固定座、伸缩杆二、限位杆、伸缩杆三、器械盘、横杆、稳固装置等；本发明结构合理简单、生产成本低、安装方便，通过设置的万向轮使装置整体更加便捷的进行移动，以及设置的器械盘无须医患人员来回走动拿取医具减少工作强度；本发明通过设置的支撑杆一、伸缩杆一、固定板一、托架、支撑杆二和绕线杆可以对装置使用时需要用到的引流管进行缠绕以及放置；本发明通过设置的稳固装置可以将垂体瘤更好的固定住便于后续的取样切割等。

摘要： 本发明公开了NFIC基因可以作为垂体瘤早期诊断的分子标志物。本发明的实验证明，与正常垂体组织相比，垂体瘤组织中NFIC基因表达显著升高，且经过RNA干扰实验证明NFIC能够影响垂体瘤细胞的增殖。根据本发明的研究成果，可以研发能够抑制NFIC基因表达的药物，从而实现临床上对于垂体瘤的预防和治疗。

摘要： 本发明公开了MUC21基因及其表达产物在垂体瘤诊疗中的用途，本发明通过生物信息学方法筛选到与垂体瘤发生发展相关的基因MUC21，并采用荧光定量等方法进行功能验证，MUC21基因在垂体瘤患者组织中表达下调，增加MUC21基因的表达可以抑制垂体瘤细胞的过度增殖。本发明还公布了诊断垂体瘤的产品和治疗垂体瘤的药物组合物。

摘要： 本发明公开了SMR3B基因在垂体瘤诊治中的应用，SMR3B基因在垂体瘤患者组织中呈差异性表达，增加SMR3B的表达可以促进垂体瘤细胞的凋亡，本发明公开了垂体瘤诊断和治疗的方法，大大提高了垂体瘤诊断的敏感性和特异性，同时为垂体瘤的基因治疗提供了新的靶点。

摘要： 本发明涉及一种垂体瘤致病基因CCNB1及其应用。本发明运用生物信息学方法筛选到一个垂体瘤致病相关基因CCNB1，并运用荧光定量PCR方法对筛选到的垂体瘤致病基因CCNB1进行功能分析，结果显示筛选得到的CCNB1与垂体瘤具有很好的相关性，可用于制备垂体瘤辅助诊断或者预后制剂。本发明还公布了一种检测CCNB1表达水平的荧光定量PCR试剂盒及其使用方法，该试剂盒灵敏度高，定量快速准确、稳定性好，具有良好的应用前景。

摘要： 本发明提供了一种快速高效地在葡萄中瞬时转化基因的转化方法。本发明将载有重组质粒的GV3101农杆菌菌株和p19菌株分别培养，等体积混合备用；选择5周龄的葡萄组培苗的植物组织，采用注射器法高压将菌液完全浸入植物组织；之后植物组织保持水分和透气；经黑暗培养和光照培养后，经检测即可用于后续实验。本发明将葡萄组培苗叶片直接置于注射器内，依靠注射器拉动带来的瞬时高压迅速的实现了农杆菌菌液的浸入，操作简单，同时减少了操作的时间，节省了人力物力和财力。另外这种方法还保证了叶片不会出现传统真空泵抽气制造高压时，由于抽气时间过长而造成的植物细胞膜破裂而引起细胞的死亡，极大地提高了转化的效率。